AnaptysBio (NASDAQ:ANAB – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
Risk & Volatility
AnaptysBio has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for AnaptysBio and Shattuck Labs, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AnaptysBio | 1 | 3 | 11 | 0 | 2.67 |
| Shattuck Labs | 1 | 0 | 9 | 2 | 3.00 |
Earnings and Valuation
This table compares AnaptysBio and Shattuck Labs”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AnaptysBio | $234.60 million | 6.83 | -$13.23 million | ($1.08) | -50.10 |
| Shattuck Labs | $1.00 million | 622.25 | -$48.81 million | ($0.51) | -12.16 |
AnaptysBio has higher revenue and earnings than Shattuck Labs. AnaptysBio is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares AnaptysBio and Shattuck Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AnaptysBio | -11.53% | N/A | -7.75% |
| Shattuck Labs | N/A | -43.57% | -40.90% |
Institutional & Insider Ownership
58.7% of Shattuck Labs shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Shattuck Labs beats AnaptysBio on 9 of the 15 factors compared between the two stocks.
About AnaptysBio
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
